Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-015731
Filing Date
2024-11-14
Accepted
2024-11-14 16:30:31
Documents
71
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q rnaz-20240930x10q.htm   iXBRL 10-Q 1286901
2 EX-31.1 rnaz-20240930xex31d1.htm EX-31.1 17026
3 EX-31.2 rnaz-20240930xex31d2.htm EX-31.2 17157
4 EX-32.1 rnaz-20240930xex32d1.htm EX-32.1 7105
5 EX-32.2 rnaz-20240930xex32d2.htm EX-32.2 6174
  Complete submission text file 0001558370-24-015731.txt   5888473

Data Files

Seq Description Document Type Size
6 EX-101.SCH rnaz-20240930.xsd EX-101.SCH 51185
7 EX-101.CAL rnaz-20240930_cal.xml EX-101.CAL 35297
8 EX-101.DEF rnaz-20240930_def.xml EX-101.DEF 142128
9 EX-101.LAB rnaz-20240930_lab.xml EX-101.LAB 406238
10 EX-101.PRE rnaz-20240930_pre.xml EX-101.PRE 295060
74 EXTRACTED XBRL INSTANCE DOCUMENT rnaz-20240930x10q_htm.xml XML 798059
Mailing Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109
Business Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109 857-301-6857
Transcode Therapeutics, Inc. (Filer) CIK: 0001829635 (see all company filings)

EIN.: 811065054 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40363 | Film No.: 241463123
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)